{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T09:31:25Z","timestamp":1787391085606,"version":"build-2736575974"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,18]]},"DOI":"10.7759\/cureus.99574","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T01:53:58Z","timestamp":1766109238000},"source":"Crossref","is-referenced-by-count":1,"title":["Severe Late-Onset Neutropenia in a Patient With Multiple Sclerosis Treated With Ocrelizumab"],"prefix":"10.7759","author":[{"given":"Mohamed K","family":"Mansour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raju","family":"Raghunathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousif","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006924","article-title":"Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis","volume":"92","author":"Cohen BA","year":"2019","unstructured":"Cohen BA. Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis. Neurology. 2019, 92:435-436. 10.1212\/WNL.0000000000006924","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116603","article-title":"Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: a case report and review of the literature","volume":"409","author":"Zanetta C","year":"2020","unstructured":"Zanetta C, Robotti M, Nozzolillo A, et al.. Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: a case report and review of the literature. J Neurol Sci. 2020, 409:116603. 10.1016\/j.jns.2019.116603","journal-title":"J Neurol Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3313-y","article-title":"Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature","volume":"35","author":"Monaco WE","year":"2016","unstructured":"Monaco WE, Jones JD, Rigby WF. Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature. Clin Rheumatol. 2016, 35:2457-2462. 10.1007\/s10067-016-3313-y","journal-title":"Clin Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130526","article-title":"Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab","volume":"41","author":"Abdulkader R","year":"2014","unstructured":"Abdulkader R, Dharmapalaiah C, Rose G, Shand LM, Clunie GP, Watts RA. Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab. J Rheumatol. 2014, 41:858-861. 10.3899\/jrheum.130526","journal-title":"J Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban X","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, et al.. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017, 376:209-220. 10.1056\/NEJMoa1606468","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/1941874420936438","article-title":"Severe delayed-onset neutropenia induced by ocrelizumab","volume":"11","author":"Baird-Gunning J","year":"2021","unstructured":"Baird-Gunning J, Yun J, Stevenson W, Ng K. Severe delayed-onset neutropenia induced by ocrelizumab. Neurohospitalist. 2021, 11:59-61. 10.1177\/1941874420936438","journal-title":"Neurohospitalist"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5299","article-title":"Severe late-onset neutropenia induced by ocrelizumab in a multiple sclerosis patient: a case report","volume":"10","author":"Rauniyar R","year":"2022","unstructured":"Rauniyar R, Rauniyar R, Agrawal A, Yadav S, Avula S. Severe late-onset neutropenia induced by ocrelizumab in a multiple sclerosis patient: a case report. Clin Case Rep. 2022, 10:e05299. 10.1002\/ccr3.5299","journal-title":"Clin Case Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.54.11.2147","article-title":"Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor","volume":"54","author":"Openshaw H","year":"2000","unstructured":"Openshaw H, Stuve O, Antel JP, et al.. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology. 2000, 54:2147-2150. 10.1212\/wnl.54.11.2147","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.11.6","article-title":"MicroRNAs: the primary cause or a determinant of progression in leukemia?","volume":"4","author":"Bousquet M","year":"2011","unstructured":"Bousquet M, Lodish HF. MicroRNAs: the primary cause or a determinant of progression in leukemia?. Expert Rev Hematol. 2011, 4:121-123. 10.1586\/ehm.11.6","journal-title":"Expert Rev Hematol"},{"key":"ref10","unstructured":"U.S. Food and Drug Administration. (2024). Ocrevus (Ocrelizumab) Prescribing Information. FDA Label Database. (2024). Accessed. August 11, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761053s035lbl.pdf."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/439077-severe-late-onset-neutropenia-in-a-patient-with-multiple-sclerosis-treated-with-ocrelizumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T01:53:59Z","timestamp":1766109239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/439077-severe-late-onset-neutropenia-in-a-patient-with-multiple-sclerosis-treated-with-ocrelizumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.99574","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,18]]}}}